Physician profile
Amy D Babin
NPI 1972581973
$2,081.46
in general payments reported to CMS, 2019-2025
27 companies · $456 in 2025
The $456 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $53.90 · 2021: $286 · 2022: $343 · 2023: $397 · 2024: $228 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $541.78 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Amgen INC. | $243.99 | 2019-2025 | Evenity, Xgeva, Prolia |
| Pfizer INC. | $167.68 | 2019-2025 | |
| Astellas Pharma US INC | $151.42 | 2023-2025 | Veozah |
| Myriad Women'S Health, INC. | $98.99 | 2023 | Myrisk |
| Hologic Sales and Service, LLC | $89.49 | 2021-2025 | Aptima, Novasure, Myosure Tissue Removal Device |
| Exeltis, USA INC. | $88.26 | 2021-2024 | Slynd |
| Axsome Therapeutics, INC. | $84.58 | 2025 | Auvelity |
| Therapeuticsmd, INC. | $75.27 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.82 | 2019-2025 | |
| Ethicon US, LLC | $57.40 | 2025 | Stratafix, Vistaseal |
| Coopersurgical, INC. | $56.64 | 2019-2022 | |
| Novo Nordisk INC | $54.03 | 2019-2025 | Wegovy |
| Evofem Biosciences, INC. | $40.26 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $35.99 | 2024-2025 | Exparel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $32.71 | 2025 | Dexcom G6 Transmitter |
| Mayne Pharma Commercial LLC | $30.08 | 2025 | |
| Organon LLC | $29.29 | 2024 | |
| Avion Pharmaceuticals | $28.59 | 2021-2022 | |
| Sage Therapeutics, LLC | $19.15 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $16.13 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $15.79 | 2021 | |
| Duchesnay USA Incorporated | $15.25 | 2019 | |
| Boston Scientific Corporation | $13.74 | 2019 | |
| Millicent US INC | $13.53 | 2025 | Intrarosa |
| Amag Pharmaceuticals, INC. | $11.30 | 2019 | |
| Lupin INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Babin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.